All things complement

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 10, 2016, Pages 1856-1866

  Thurman, Joshua M ^a   Nester, Carla M ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Clinical immunology; Complement; Complement activation; Complement inactivating agents; Complement system proteins; Glomerular disease; Glomerulonephritis; Humans; Immune complexes; Kidney diseases; Kidney glomerulus; Lupus nephritis

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AUTOANTIBODY; C REACTIVE PROTEIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT FACTOR D; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; ECULIZUMAB; IMMUNOGLOBULIN G; MANNOSE BINDING LECTIN; MEMBRANE COFACTOR PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN; PROPERDIN; THROMBOMODULIN; UNINDEXED DRUG; BIOLOGICAL MARKER; COMPLEMENT;

ARTICLE; AUTOIMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; ELECTRON MICROSCOPY; GENETIC DISORDER; GLOMERULOPATHY; HUMAN; IMMUNE MEDIATED INJURY; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MESANGIUM; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PODOCYTE; STAINING; ANIMAL; DISEASE MODEL; GLOMERULUS; KIDNEY DISEASE; METABOLISM; PATHOLOGY;

ANIMALS; BIOMARKERS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS;

EID: 85013451941     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01710216     Document Type: Article

References (95)

1. Ricklin D, Hajishengallis G, Yang K, Lambris JD: Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797, 2010
2. Mathern DR, Heeger PS: Molecules Great and Small: The Complement System. Clin J Am Soc Nephrol 10: 1636-1650, 2015
3. Walport MJ: Complement. First of two parts. N Engl J Med 344: 1058-1066, 2001
4. Truedsson L, Bengtsson AA, Sturfelt G: Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40: 560-566, 2007
5. Manderson AP, Botto M, Walport MJ: The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22: 431-456, 2004
6. Hiemstra PS, Gorter A, Stuurman ME, Van Es LA, Daha MR: Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol 17: 321-326, 1987
7. Ollert MW, Kadlec JV, David K, Petrella EC, Bredehorst R, Vogel CW: Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol 153: 2213-2221, 1994
8. Wan JX, Fukuda N, Endo M, Tahira Y, Yao EH, Matsuda H, Ueno T, Matsumoto K: Complement 3 is involved in changing the phenotype of human glomerular mesangial cells. J Cell Physiol 213: 495-501, 2007
9. Thurman JM, Lenderink AM, Royer PA, Coleman KE, Zhou J, Lambris JD, Nemenoff RA, Quigg RJ, Holers VM: C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol 178: 1819-1828, 2007
10. Benzaquen LR, Nicholson-Weller A, Halperin JA: Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179: 985-992, 1994
11. Lovett DH, Haensch GM, Goppelt M, Resch K, Gemsa D: Activation of glomerular mesangial cells by the terminal membrane attack complex of complement. J Immunol 138: 2473-2480, 1987
12. Adler S, Baker PJ, Johnson RJ, Ochi RF, Pritzl P, Couser WG: Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J Clin Invest 77: 762-767, 1986
13. Cybulsky AV, Rennke HG, Feintzeig ID, Salant DJ: Complementinduced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy. J Clin Invest 77: 1096-1107, 1986
14. Zipfel PF, Skerka C: Complement regulators and inhibitory proteins. Nat Rev Immunol 9: 729-740, 2009
15. Janatova J, Tack BF: Fourth component of human complement: studies of an amine-sensitive site comprised of a thiol component. Biochemistry 20: 2394-2402, 1981
16. Ichida S, Yuzawa Y, Okada H, Yoshioka K, Matsuo S: Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 46: 89-96, 1994
17. Kajander T, Lehtinen MJ, Hyvärinen S, Bhattacharjee A, Leung E, Isenman DE, Meri S, Goldman A, Jokiranta TS: Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A 108: 2897-2902, 2011
18. Józsi M, Tortajada A, Uzonyi B, Goicoechea de Jorge E, Rodríguez de Córdoba S: Factor H-related proteins determine complement-activating surfaces. Trends Immunol 36: 374-384, 2015
19. Thurman JM, Ljubanovi_c D, Royer PA, Kraus DM, Molina H, Barry NP, Proctor G, Levi M, Holers VM: Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 116: 357-368, 2006
20. Farrar CA, Zhou W, Lin T, Sacks SH: Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 20: 217-226, 2006
21. Krisinger MJ, Goebeler V, Lu Z, Meixner SC, Myles T, Pryzdial EL, Conway EM: Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 120: 1717-1725, 2012
22. Renner B, Tong HH, Laskowski J, Jonscher K, Goetz L, Woolaver R, Hannan J, Li YX, Hourcade D, Pickering MC, Holers VM, Thurman JM: Annexin A2 Enhances Complement Activation by Inhibiting Factor H. J Immunol 196: 1355-1365, 2016
23. Cochrane CG, Unanue ER, Dixon FJ: A Role of Polymorphonuclear Leukocytes and Complement in Nephrotoxic Nephritis. J Exp Med 122: 99-116, 1965
24. Wilson CB, Dixon FJ: Immunopathology and glomerulonephritis. Annu Rev Med 25: 83-98, 1974
25. Sethi S, Nasr SH, De Vriese AS, Fervenza FC: C4d as a Diagnostic Tool in ProliferativeGN. J AmSocNephrol 26: 2852-2859, 2015
26. Verroust PJ, Wilson CB, Cooper NR, Edgington TS, Dixon FJ: Glomerular complement components in human glomerulonephritis. J Clin Invest 53: 77-84, 1974
27. Pickering MC, D’Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT: C3 glomerulopathy: consensus report. Kidney Int 84: 1079-1089, 2013
28. Hebert LA, Cosio FG, Neff JC: Diagnostic significance of hypocomplementemia. Kidney Int 39: 811-821, 1991
29. Vallota EH, Forristal J, Spitzer RE, Davis NC, West CD: Continuing C3 breakdown after bilateral nephrectomy in patients with membrano-proliferative glomerulonephritis. J Clin Invest 50: 552-558, 1971
30. Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB: Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 31: 632-641, 1988
31. Brenchley PE, Coupes B, Short CD, O’Donoghue DJ, Ballardie FW, Mallick NP: Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int 41: 933-937, 1992
32. Bu F, Meyer NC, Zhang Y, Borsa NG, Thomas C, Nester C, Smith RJ: Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome. Am J Kidney Dis 65: 968-969, 2015
33. Høgåsen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M: Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 95: 1054-1061, 1995
34. Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS: Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 164: 786-794, 2000
35. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M: Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 31: 424-428, 2002
36. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC: Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170: 52-64, 2007
37. Lenderink AM, Liegel K, Ljubanovi_c D, Coleman KE, Gilkeson GS, Holers VM, Thurman JM: The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am J Physiol Renal Physiol 293: F555-F564, 2007
38. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT: Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146-151, 1990
39. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL: Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 97: 2259-2267, 1998
40. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25: 1256-1264, 2007
41. Sahu A, Morikis D, Lambris JD: Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol Immunol 39: 557-566, 2003
42. Ebanks RO, Isenman DE: Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity. Mol Immunol 33: 297-309, 1996
43. Alexander JJ, Hack BK, Cunningham PN, Quigg RJ: A protein with characteristics of factor H is present on rodent platelets and functions as the immune adherence receptor. J Biol Chem276: 32129-32135, 2001
44. Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, Katz LM, Sethi S, Smith RJ: Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 7: 265-274, 2012
45. Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V: Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82: 454-464, 2012
46. Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676-1687, 2009
47. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M; EuropeanWorking Party on Complement Genetics in Renal Diseases: Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24: 475-486, 2013
48. Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A, Wood KM, Goodship JA, Goodship TH: Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 3: e431, 2006
49. Maga TK, Meyer NC, Belsha C, Nishimura CJ, Zhang Y, Smith RJ: A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome. Nephrol Dial Transplant 26: 739-741, 2011
50. Eyler SJ, Meyer NC, Zhang Y, Xiao X, Nester CM, Smith RJ: A novel hybrid CFHR1/CFHgene causes atypical hemolytic uremic syndrome. Pediatr Nephrol 28: 2221-2225, 2013
51. Valoti E, Alberti M, Tortajada A, Garcia-Fernandez J, Gastoldi S, Besso L, Bresin E, Remuzzi G, Rodriguez de Cordoba S, Noris M: A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J Am Soc Nephrol 26: 209-219, 2015
52. Francis NJ, McNicholas B, Awan A, Waldron M, Reddan D, Sadlier D, Kavanagh D, Strain L, Marchbank KJ, Harris CL, Goodship TH: A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood 119: 591-601, 2012
53. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong HI, Hari P, LeQuintrec M, Niaudet P, Loirat C, Fridman WH, Frémeaux-Bacchi V: Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21: 2180-2187, 2010
54. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ: C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 82: 465-473, 2012
55. Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F: Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44: 193-199, 2007
56. Tortajada A, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, Alba-Domínguez M, Malik TH, Bedoya R, Cabrera Pérez R, López Trascasa M, Pickering MC, Harris CL, Sánchez-Corral P, Llorca O, Rodríguez de Córdoba S: C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 123: 2434-2446, 2013
57. Martínez-Barricarte R, Heurich M, Valdes-Cañedo F, Vazquez-Martul E, Torreira E, Montes T, Tortajada A, Pinto S, Lopez-Trascasa M, Morgan BP, Llorca O, Harris CL, Rodríguez de Córdoba S: Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 120: 3702-3712, 2010
58. Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van deWalle J, Vivarelli M, Fremeaux-Bacchi V: for HUSI: An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31: 15-39, 2015
59. Fries LF, Gaither TA, Hammer CH, Frank MM: C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med 160: 1640-1655, 1984
60. Quigg RJ, Lim A, Haas M, Alexander JJ, He C, Carroll MC: Immune complex glomerulonephritis in C4-and C3-deficient mice. Kidney Int 53: 320-330, 1998
61. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5: 1844-1859, 2010
62. Chua JS, Baelde HJ, Zandbergen M, Wilhelmus S, van Es LA, de Fijter JW, Bruijn JA, Bajema IM, Cohen D: Complement Factor C4d Is a CommonDenominator in Thrombotic Microangiopathy. J Am Soc Nephrol 26: 2239-2247, 2015
63. Laskowski J, Renner B, Le Quintrec M, Panzer S, Hannan JP, Ljubanovic D, Ruseva MM, Borza DB, Antonioli AH, Pickering MC, Holers VM, Thurman JM: Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. Kidney Int 2016, in press
64. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
65. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RA, Lambeau G: Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371: 2277-2287, 2014
66. Teixeira JE, Costa RS, Lachmann PJ, Würzner R, Barbosa JE: CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients. Clin Exp Immunol 105: 497-503, 1996
67. Floege J, Moura IC, Daha MR: Newinsights into the pathogenesis of IgA nephropathy. Semin Immunopathol 36: 431-442, 2014
68. Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J: Current Understanding of the Role of Complement in IgA Nephropathy. J Am Soc Nephrol 26: 1503-1512, 2015
69. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP: Genomewide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43: 321-327, 2011
70. Zhai YL, Meng SJ, Zhu L, Shi SF, Wang SX, Liu LJ, Lv JC, Yu F, Zhao MH, Zhang H: Rare Variants in the Complement Factor HRelated Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy [published online ahead of print January 29, 2016]. J Am Soc Nephrol doi:10.1681/ASN.2015010012
71. Hsu SI, Couser WG: Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol 14[Suppl 2]: S186-S191, 2003
72. Sheerin NS, Risley P, Abe K, Tang Z, Wong W, Lin T, Sacks SH: Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB J 22: 1065-1072, 2008
73. Nath KA, Hostetter MK, Hostetter TH: Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 76: 667-675, 1985
74. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C: Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8: 554-562, 2013
75. Bhattacharjee A, Reuter S, Trojnár E, Kolodziejczyk R, Seeberger H, Hyvärinen S, Uzonyi B, Szilágyi Á, Prohászka Z, Goldman A, Józsi M, Jokiranta TS: The major autoantibody epitope on factorH in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease. J Biol Chem 290: 9500-9510, 2015
76. Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR, Botto M: Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 204: 1249-1256, 2007
77. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C: Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368: 2169-2181, 2013
78. Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, VandeWalle J, Ogawa M, Bedrosian CL, Licht C: Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89: 701-711, 2016
79. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, Inazawa J, Kinoshita T, Kanakura Y: Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370: 632-639, 2014
80. Zuber J, Quintrec ML, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noel LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C: Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation. Am J Transplant 12: 3337-3354, 2012
81. Tang Z, Lu B, Hatch E, Sacks SH, Sheerin NS: C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol 20: 593-603, 2009
82. Rose KL, Paixao-Cavalcante D, Fish J, Manderson AP, Malik TH, Bygrave AE, Lin T, Sacks SH, Walport MJ, Cook HT, Botto M, Pickering MC: Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 118: 608-618, 2008
83. Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P, Smith RJ: Atypical aHUS: State of the art. Mol Immunol 67: 31-42, 2015
84. Fakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Couzi L, Essig M, Ribes D, Dragon-Durey MA, Bridoux F, Rondeau E, Frémeaux-Bacchi V: Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21: 859-867, 2010
85. Vivarelli M, Emma F: Treatment of C3 glomerulopathy with complement blockers. Semin Thromb Hemost 40: 472-477, 2014
86. Shapira I, Andrade D, Allen SL, Salmon JE: Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 64: 2719-2723, 2012
87. Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L, Terence Cook H, Cairns TD: Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 54: 2286-2288, 2015
88. Rosenblad T, Rebetz J, Johansson M, Békássy Z, Sartz L, Karpman D: Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 29: 2225-2228, 2014
89. Ricklin D, Lambris JD: Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 190: 3839-3847, 2013
90. Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC: C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25: 225-231, 2014
91. Thurman JM, Le Quintrec M: Targeting the Complement Cascade: Novel Treatments Coming down the Pike. Kidney Int 2016, in press
92. Skattum L, van Deuren M, van der Poll T, Truedsson L: Complement deficiency states and associated infections. Mol Immunol 48: 1643-1655, 2011
93. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P: Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117: 6786-6792, 2011
94. Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G: Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124: 1715-1726, 2014
95. Haas M, Eustace JA: Immune complex deposits in ANCAassociated crescentic glomerulonephritis: a study of 126 cases. Kidney Int 65: 2145-2152, 2004